

Bangladesh support for Pneumococcal vaccine

This decision letter sets out the programme terms of a programme.

1. Country: Bangladesh			
2. Grant number: 1316-BGD-12b-X / 1316-BGD-12b-Y			
3. Date of decision letter: 18 November 2015			
4. Date of the partnership framework agreement: 24/06/2013			
5. Programme title: New vaccine support (NVS), Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV10), 2 dose(s) per vial , LIQUID			
8. Programme duration⁵: 2014 - 2016 ⁶			
9. Programme budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)			
	2014-2015	2016	Total ⁷
Programme budget (US\$)	US\$45,914,000 ⁸	US\$40,513,000	US\$86,427,000
10. Vaccine introduction grant (in US\$): Not applicable.			
11. Indicative annual amounts: (subject to the terms of the partnership framework agreement, if applicable) ⁹			
Type of supplies to be purchased with GAVI funds in each year (1316-BGD-12b-X)	2014-2015	2016	
Vaccine Doses		8,386,800	
Annual Amounts (US\$)	US\$45,171,000	US\$40,069,000	
Type of supplies to be purchased with GAVI funds in each year (1316-BGD-12b-Y)	2014-2015	2016	
AD Syringes		8,710,200	
Re-constitution Syringes		0	
Safety Boxes		95,825	
Annual Amounts (US\$)	US\$743,000	US\$444,000	

⁵ This is the entire duration of the programme.

⁶ Programme did not begin until 2015 due to delay in introduction.

⁷ This is the total amount endorsed by Gavi for the entire duration of the programme.

⁸ This is the consolidated amount for all previous years.

⁹ This is the amount that Gavi has approved.

12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.															
13. Self-procurement: Not applicable															
<p>14. Co-financing obligations: Reference code: 1316-BGD-12b-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <tr> <td>Type of supplies to be purchased with Country funds in each year</td> <td>2016</td> </tr> <tr> <td>Number of vaccine doses</td> <td>515,600</td> </tr> <tr> <td>Number of AD syringes</td> <td></td> </tr> <tr> <td>Number of re-constitution syringes</td> <td></td> </tr> <tr> <td>Number of safety boxes</td> <td></td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$1,739,128</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>US\$1,780,500</td> </tr> </table>		Type of supplies to be purchased with Country funds in each year	2016	Number of vaccine doses	515,600	Number of AD syringes		Number of re-constitution syringes		Number of safety boxes		Value of vaccine doses (US\$)	US\$1,739,128	Total co-financing payments (US\$) (including freight)	US\$1,780,500
Type of supplies to be purchased with Country funds in each year	2016														
Number of vaccine doses	515,600														
Number of AD syringes															
Number of re-constitution syringes															
Number of safety boxes															
Value of vaccine doses (US\$)	US\$1,739,128														
Total co-financing payments (US\$) (including freight)	US\$1,780,500														
15. Operational support for campaigns: Not applicable															
16. Additional reporting requirements: Not applicable															
Reports and other information	Due dates														
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016														
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat														
<p>17. Financial clarifications: The Country shall provide the following clarifications to Gavi*: Not applicable</p> <p><i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i></p>															
18. Other conditions: The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.															

Signed by,



On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
18 November 2015

Bangladesh support for Measles Rubella vaccine

This decision letter sets out the programme terms of a programme.

1. Country: Bangladesh			
2. Grant number: 1216-BGD-09a-X / 1316-BGD-09a-Y			
3. Date of decision letter: 18 November 2015			
4. Date of the partnership framework agreement: 24/06/2013			
5. Programme title: New vaccine support (NVS), Measles second dose Routine			
6. Vaccine type: Measles-Rubella			
7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED			
8. Programme duration¹: 2012 - 2016			
9. Programme budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)			
	2012-2015	2016	Total ²
Programme budget (US\$)	US\$7,242,538 ³	US\$1,471,000	US\$8,713,538
10. Vaccine introduction grant (in US\$): Not applicable.			
11. Indicative annual amounts: (subject to the terms of the partnership framework agreement, if applicable) ⁴			
Type of supplies to be purchased with GAVI funds in each year (1216-BGD-09a-X)	2012-2015	2016	
Vaccine Doses		3,802,000	
Annual Amounts (US\$)	US\$6,574,538	US\$1,353,000	
Type of supplies to be purchased with GAVI funds in each year (1316-BGD-09a-Y)	2012-2015	2016	
AD Syringes		1,984,600	
Re-constitution Syringes		418,300	
Safety Boxes		26,450	
Annual Amounts (US\$)	US\$668,000	US\$118,000	
12. Procurement agency: UNICEF.			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

13. Self-procurement: Not applicable.	
14. Co-financing obligations: Not applicable	
15. Operational support for campaigns: Not applicable	
16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: The Country shall provide the following clarifications to Gavi*: Not applicable	
<i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i>	
18. Other conditions:	
Country has presented an official request to Gavi to switch from measles vaccine to measles- rubella vaccine for the routine measles second dose with country funding for the equivalent cost of the rubella component. As such, country will make the required payments to UNICEF SD as indicated in the table below.	
	2016
Number of doses of vaccines for Measles Second Dose approved by Gavi.	3,802,000
Amount for vaccines approved by Gavi in US\$ (excluding freight and insurance).	\$1,216,640
Number of doses of Measles-Rubella vaccine that can be purchased with Gavi support.	1,994,492
Number of doses of Measles-Rubella vaccine to be funded by country.	1,807,508
Amount for Measles-Rubella vaccines to be funded by country (excluding freight and insurance).	\$1,102,580
Country understands that vaccines will be purchased only after receipt of full payment of the respective amounts due from Country and Gavi by the procurement agency for the number of doses as indicated in this Decision Letter. In the event that country wishes to revert to measles vaccine, country should inform UNICEF and Gavi immediately in order to agree on an appropriate arrangement.	

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

18 November 2015

Bangladesh support for Pentavalent vaccine

This decision letter sets out the programme terms of a programme.

1. Country: Bangladesh			
2. Grant number: 16-BGD-04a-X / 16-BGD-04a-Y			
3. Date of decision letter: 18 November 2015			
4. Date of the partnership framework agreement: 24/06/2013			
5. Programme title: New vaccine support (NVS), Pentavalent Routine			
6. Vaccine type: Pentavalent			
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 1 dose(s) per vial, LIQUID			
8. Programme duration¹⁰: 2009 - 2016			
9. Programme budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)			
	2009-2015	2016	Total ¹¹
Programme budget (US\$)	US\$198,996,750 ¹²	US\$15,854,500	US\$214,851,250
10. Vaccine introduction grant (in US\$): Not applicable.			
11. Indicative annual amounts: (subject to the terms of the partnership framework agreement, if applicable) ¹³			
Type of supplies to be purchased with GAVI funds in each year (16-BGD-04a-X)	2009-2015	2016	
Vaccine Doses		8,389,000	
Annual Amounts (US\$)	US\$194,192,750	US\$15,355,000	
Type of supplies to be purchased with GAVI funds in each year (16-BGD-04a-Y)	2009-2015	2016	
AD Syringes		9,802,200	
Re-constitution Syringes		0	
Safety Boxes		107,825	
Annual Amounts (US\$)	US\$4,804,000	US\$499,500	

¹⁰ This is the entire duration of the programme.


¹¹ This is the total amount endorsed by Gavi for the entire duration of the programme.

¹² This is the consolidated amount for all previous years.

¹³ This is the amount that Gavi has approved.

12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.	
13. Self-procurement: Not applicable	
14. Co-financing obligations: Reference code: 16-BGD-04a-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.	
Type of supplies to be purchased with Country funds in each year	2016
Number of vaccine doses	992,900
Number of AD syringes	
Number of re-constitution syringes	
Number of safety boxes	
Value of vaccine doses (US\$)	US\$1,784,270
Total co-financing payments (US\$) (including freight)	US\$1,876,500
15. Operational support for campaigns: Not applicable	
16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: The Country shall provide the following clarifications to Gavi*: Not applicable <i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i>	
18. Other conditions: The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.	

Signed by,



On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
18 November 2015